OBJECTIVE: To investigate the long-term efficacy and safety of a botulinum toxin type A (BoNT-A) for the treatment of cervical dystonia (CD). METHODS: We conducted a retrospective chart review of patients with CD treated with abobotulinumtoxinA (Dysport™ 100-800 units [U] for injection) between 1993 and 2009 at the University Hospital "La Paz" (LPUH). Affected muscles were selected using electromyography (EMG). RESULTS: Thirty-seven patients were included in the study; most were female (62%) and had idiopathic CD (60%). Almost half (46%) of patients were diagnosed with the condition more than 10 years ago. The most common clinical presentations of CD were rotation (46%) and laterocollis (43%). On average, patients were treated with Dysport for 7 years (range: 1-17 years) and received 487 (range: 320 to 650) U over 15.9 (range: 1 to 40) injection cycles. Most (97%) patients maintained a response from treatment initiation to end of evaluation period. Overall, 70% of patients were taking concomitant oral medication. Dysport was generally well tolerated. Dysphagia was reported by 18.9% of patients, but this did not lead to discontinuation of Dysport treatment. CONCLUSION: These data confirm the long-term efficacy and safety of Dysport in CD over a period of up to 17 years.
OBJECTIVE: To investigate the long-term efficacy and safety of a botulinum toxin type A (BoNT-A) for the treatment of cervical dystonia (CD). METHODS: We conducted a retrospective chart review of patients with CD treated with abobotulinumtoxinA (Dysport™ 100-800 units [U] for injection) between 1993 and 2009 at the University Hospital "La Paz" (LPUH). Affected muscles were selected using electromyography (EMG). RESULTS: Thirty-seven patients were included in the study; most were female (62%) and had idiopathic CD (60%). Almost half (46%) of patients were diagnosed with the condition more than 10 years ago. The most common clinical presentations of CD were rotation (46%) and laterocollis (43%). On average, patients were treated with Dysport for 7 years (range: 1-17 years) and received 487 (range: 320 to 650) U over 15.9 (range: 1 to 40) injection cycles. Most (97%) patients maintained a response from treatment initiation to end of evaluation period. Overall, 70% of patients were taking concomitant oral medication. Dysport was generally well tolerated. Dysphagia was reported by 18.9% of patients, but this did not lead to discontinuation of Dysport treatment. CONCLUSION: These data confirm the long-term efficacy and safety of Dysport in CD over a period of up to 17 years.
Authors: A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca Journal: Neurotox Res Date: 2017-05-06 Impact factor: 3.911
Authors: Martina Petracca; Maria Rita Lo Monaco; Tamara Ialongo; Enrico Di Stasio; Maria Luana Cerbarano; Loredana Maggi; Alessandro De Biase; Giulia Di Lazzaro; Paolo Calabresi; Anna Rita Bentivoglio Journal: J Neurol Date: 2022-09-06 Impact factor: 6.682
Authors: Vijay P Misra; Edvard Ehler; Benjamin Zakine; Pascal Maisonobe; Marion Simonetta-Moreau Journal: BMJ Open Date: 2012-06-14 Impact factor: 2.692